| NCT07211958 | Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation | NOT_YET_RECRUITING | PHASE3 | 2025-12 | 2031-01 | 2029-06 |
| NCT06226571 | A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias | RECRUITING | PHASE1 | 2024-05-21 | 2027-02 | 2027-02 |
| NCT06132256 | MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | RECRUITING | PHASE2 | 2023-12-11 | 2026-11 | 2026-09 |
| NCT05731947 | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2023-04-04 | 2027-08 | 2025-12 |
| NCT05406817 | Study of Radiolabeled Revumenib in Adults With Acute Leukemia | COMPLETED | PHASE1 | 2022-08-05 | 2024-11-18 | 2024-11-18 |
| NCT05326516 | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | COMPLETED | PHASE1 | 2022-03-09 | 2024-07-29 | 2024-07-29 |
| NCT04710576 | A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-03-04 | 2027-12 | 2023-04-07 |
| NCT04415073 | A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 | TERMINATED | PHASE2 | 2020-05-30 | 2020-07-13 | 2020-07-13 |
| NCT04065399 | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | RECRUITING | PHASE1, PHASE2 | 2019-11-05 | 2027-12-15 | 2027-12-15 |
| NCT03604692 | A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD | COMPLETED | PHASE1, PHASE2 | 2018-11-01 | 2024-10-18 | 2022-08-12 |
| NCT03238027 | A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors | COMPLETED | PHASE1 | 2017-09-01 | 2020-11-20 | 2020-11-20 |
| NCT03192111 | A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function | COMPLETED | PHASE1 | 2017-07-27 | 2017-11-23 | 2017-11-23 |
| NCT03187015 | A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects | COMPLETED | PHASE1 | 2017-05-23 | 2017-08-22 | 2017-06-04 |
| NCT02915523 | Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer | COMPLETED | PHASE1, PHASE2 | 2016-12-19 | 2021-04-21 | 2019-02-21 |
| NCT02922933 | A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects | COMPLETED | PHASE1 | 2016-10-25 | 2017-05-08 | 2017-04-19 |
| NCT02922946 | Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat | COMPLETED | PHASE1 | 2016-10-11 | 2017-06-26 | 2017-05-20 |
| NCT02909452 | Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | COMPLETED | PHASE1 | 2016-09-20 | 2021-02-09 | 2019-07-17 |
| NCT02897778 | Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors | COMPLETED | PHASE1 | 2016-08-24 | 2017-03-13 | 2017-03-13 |
| NCT02820961 | Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer | COMPLETED | PHASE1 | 2016-06-29 | 2021-07-12 | 2018-09-10 |
| NCT02708680 | Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In | COMPLETED | PHASE1, PHASE2 | 2016-05 | 2021-03-31 | 2021-03-31 |
| NCT02437136 | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) | COMPLETED | PHASE1, PHASE2 | 2015-08-26 | 2022-09-29 | 2022-09-29 |
| NCT02115594 | Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer | WITHDRAWN | PHASE2 | 2014-04 | 2016-06 | 2015-12 |
| NCT01594398 | Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer | COMPLETED | PHASE1 | 2012-05 | 2014-05 | 2014-04 |
| NCT00866333 | A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma | TERMINATED | PHASE2 | 2009-04-13 | 2013-02-08 | 2013-02-08 |
| NCT00828854 | Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing | COMPLETED | PHASE2 | 2008-10-01 | 2009-11-24 | 2009-11-24 |
| NCT00750698 | A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib | TERMINATED | PHASE2 | 2008-08 | 2010-06 | 2010-05 |
| NCT00676663 | Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer | COMPLETED | PHASE2 | 2008-06-13 | 2012-11-26 | 2011-01-29 |
| NCT00754312 | A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer | TERMINATED | PHASE1 | 2008-06 | 2009-02-28 | 2009-02-28 |
| NCT00602030 | Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC | COMPLETED | PHASE1, PHASE2 | 2008-01-08 | 2012-02-01 | 2010-02-04 |